Hematology: Myelodysplastic syndrome — Stem cell transplant. Treatment
Stem cell transplantation is the main treatment for myelodysplastic syndrome. However, due to life-threatening complications, this procedure can be suggested to a small proportion of patients only. The candidates for transplantation are usually considered the patients under 60 years old, with a good performance status.
On the eve of the procedure, the patient consults an oncologist. The physician clarifies complaints, conducts clinical examination and collects the case history. Additionally, the physician prescribes:
- complete blood count,
- blood chemistry,
- cytogenetic analysis.
According to the test findings, the overall condition of the patient and implantation risks are assessed.
Stem cells are transplanted from a related, or rarely strange (histologically compatible) donor. This type of transplantation is called allogeneic. For the procedure, the patient is hospitalized for 16 days. S/he receives a careful care and supervision in the clinic.
The donor cells are administered by intravenous infusion under the supervision of a hematologist. The procedure is carried out in the patient’s ward and takes no more than 1.5 hours.
The process of healthy material rooting lasts for several weeks. The first 2 weeks are the most difficult for patients. During this period, they report malaise, nausea, and increased gum bleeding. The required medicines are prescribed to alleviate the sufferings. The cost of medication is determined by the treatment intensity.
During the entire period of rehabilitation, the patient stays in an isolated ward, in which a strict hygienic regime is maintained. Such a measure is required for prevention of infectious diseases.
Recommendations for further treatment are developed for each case individually.Hide
Haven't found Your diagnosis yet?
Send an inquiry to get a cost estimate on: